

Comparison of cardiotoxicity of levobupivacaine and bupivacaine with the brain natriuretic peptide

Levobupivakain ve bupivakainin kardiyotoksiste-sinin B-type natriüretik peptid ile karşılaştırılması

Korgün Ökmen M.D.^a, Nermin Göğüş M.D.^b

a. University of Health Sciences, Bursa Yüksek İhtisas Training and Research Hospital, Department of Anesthesiology and Reanimation, Bursa/TURKEY

b. University of Health Sciences, Ankara Numune Training and Research Hospital, Department of Anesthesiology and Reanimation, Ankara /TURKEY

Corresponding author: Korgün Ökmen (M.D.), University of Health Sciences, Bursa Yüksek İhtisas Training and Research Hospital, Department of Anesthesiology and Reanimation, Mimar Sinan Quarter, Emniyet Street. 16130 Bursa/TURKEY.

E-mail: korgunokmen@gmail.com

Received/Accepted: January 22, 2018 / June 21, 2018

Conflict of interest: There is not a conflict of interest.

SUMMARY

Objective: Local anesthetics are also considered to be potentially toxic to the cardiovascular system since they act on ion channels in nerve cell membranes as well as in other tissues that can be stimulated. In this study we aimed to compare cardiotoxicity levels of both drugs with brain natriuretic peptide (BNP) protein level in patients undergoing combined spinal epidural anesthesia and postoperative analgesia when given bupivacaine and levobupivacaine at equipotent doses.

Method: In this prospective, randomized, double-blind study a total of 30 patients, aged 25-70 years, who were included in the American Society of Anesthesiologists (ASA) I-III risk class and underwent total knee arthroplasty surgery, were included in the study. Patients were randomized as Group I (n = 15) Levobupivacaine and Group II (n = 15) bupivacaine and combined spinal-epidural anesthesia was administered. The operation follow-up of patients were evaluated with the systolic arterial pressure (SAB), the diastolic arterial pressure (DAB), the mean arterial pressure (MAP) and the heart rate (HR), and postoperative follow-up with SAB, DAB, KH, visual analogue scale (VAS) values were monitored at zero minute, 1st, 6th, 12th and 24th hour. BNP levels were measured at 5th minute after spinal anesthesia, sensory block at thoracic level 10 and post-operative 24th hour.

Results: A statistically significant difference was found in the VAS values measured at postoperative 12th hour and 24th hour in favor of levobupivacaine group (p < 0.05). In the comparison of BNP levels between the groups, there was no statistically significant difference between the two groups at all measurement times (p > 0.05).

Conclusions: Similar results were obtained in intraoperative and postoperative BNP levels when using levobupivacaine and bupivacaine in equal doses for both spinal anesthesia and epidural analgesia.

Keywords: Bupivacaine, Levobupivacaine, Brain Natriuretic peptide, Cardiotoxicity

ÖZET

Amaç: Lokal anestezikler, sinir hücre membranlarındaki iyon kanalları üzerinden oluşturdukları etkileri, uyarılabilir diğer dokularda da oluşturduklarından kardiyovasküler sistem için de potansiyel toksik olarak kabul edilmektedirler. Bu çalışmada, levobupivakain ve bupivakainin kombine spinal-epidural anestezi ve analjezideki kardiyotoksiste etkilerini B-type natriüretik peptid (BNP) protein düzeyiyle saptamayı amaçladık.

Yöntem: Bu prospektif, randomize, çift kör çalışmada 25-70 yaşları arasında American Society of Anesthesiologists (ASA) I-III sınıfında olan ve total diz artroplastisi cerrahisi uygulanan toplam 30 hasta dahil edildi. Hastalar Grup I (n = 15) Levobupivakain and in Grup II (n = 15) Bupivakain olacak şekilde randomize edildi ve kombine spinal-epidural anestezi uygulandı. Hastaların ameliyat sırasındaki takipleri sistolik arteriyel basınç (SAB), diastolik arteriyel basınç (DAB), ortalama arteriyel basınç (OAB) ve kalp atım hızı (KAH) ve ameliyat sonrası takipleri ise 0. dakika ve 1., 6.,

12., 24. saatlerde SAB, DAB, KH, vizüel analog skala (VAS) değerleri izlenerek yapıldı. Spinal anestezi sonrası 5. dakika, Duyusal blok Torakal 10 düzeyinde ve ameliyat sonrası 24. saat BNP düzeyleri ölçüldü.

Bulgular: Postoperatif 12. ve 24. saatteki VAS değerlerinde levobupivakain grubu lehine istatistiksel olarak anlamlı fark bulundu ($p < 0.05$). Gruplar arası BNP düzeylerindeki karşılaştırmada tüm ölçüm zamanlarında her iki grup arasında istatistiksel olarak anlamlı bir fark saptanmadı ($p > 0.05$).

Sonuç: Levobupivakain ve bupivakainin hem spinal anestezi hem de epidural analjezi için eşit dozlarda kullanımında intraoperatif ve postoperatif BNP düzeylerinde benzer sonuçlara ulaşılmıştır.

Anahtar sözcükler: Bupivakain, Levobupivakain, Brain Natriuretic peptid, Kardiyotoksisite

INTRODUCTION

Regional anesthesia methods are currently being used for postoperative pain palliation as well as for surgical applications¹. Neuroaxial blocks such as spinal and epidural can be used individually or in combination¹. Combined spinal epidural anesthesia (CSEA) in which spinal and epidural anesthesia are applied together with a special set because they have different disadvantages when applied individually, are provided with a rapid start by spinal application and the duration of operation can be prolonged via epidural catheter and analgesia can be achieved in postoperative period². For this purpose, local anesthetic (LA) and local anesthetic + opioid combinations can be used individually. Although there are positive aspects compared to general anesthesia, direct cardiac side effects and indirect cardiac side effects due to sympathetic denervation can be seen in relation to the chemical structure and block level of LA used³.

Local anesthetics are also considered to be potentially toxic to the cardiovascular system since they act on ion channels in nerve cell membranes as well as in other tissues that can be stimulated^{4,5}. One of the most commonly used local anesthetics called Bupivacaine is the most prominent cardiac depressant^{6,7}. Levobupivacaine, another local anesthetic used for epidural and spinal anesthesia, is a newer drug. Bupivacaine's s (-) enantiomer, Levobupivacaine, has similar pharmacokinetic properties to racemic bupivacaine. Although studies have shown that levobupivacaine has less cardiovascular side effects than bupivacaine, and that anesthetic, analgesic and hemodynamic effects after intrathecal administration are similar to bupivacaine, there are also studies that report different opinions^{6,7}.

Natriuretic peptides are produced by the heart and are released by the ventricular myocardium in response to increased left ventricular wall tension and volume⁸. A number of studies on non-surgical patients with or without symptomatic heart disease

have shown that brain natriuretic peptide (BNP) has a diagnostic and prognostic value in possible myocardial injury⁸. We hypothesize that levobupivacaine is less cardiotoxic than bupivacaine.

In our study we aimed to compare cardiotoxicity levels of both drugs with BNP protein level, a cardiac burden indicator, in patients undergoing combined spinal epidural anesthesia and postoperative analgesia when given bupivacaine and levobupivacaine at equipotent doses.

MATERIAL AND METHODS

For this prospective, randomized, double-blind study, 40 patients admitted to total knee replacement (TDP) surgery with combined spinal epidural anesthesia were evaluated for compliance after local ethics committee's approval was obtained. (Ankara Numune Education and Research Hospital Ethics Committee. Ethical number: 2008/4)

Patients:

The inclusion criterias were: 1) between the ages of 20-70, 2) those who agreed to participate in the study, 3) patients included in the ASA I-III risk class

Exclusion criterias were: 1) presence of a cardiac disease, 2) use of known cardiotoxic drug, 3) use of alcohol, 4) smoking, 5) systemic disease such as diabetes mellitus (DM), hypertension (HT), 6) infection in the lumbar region, 7) those with anomalous deformities in the lumbar region, 8) those with hypersensitivity to the agents to be used in the study, 9) patients with neuromuscular disease, 10) patients with psychiatric disorders, 11) patients with morbid obesity, 12) patients who can not cooperate, and 13) patients whose preoperative and postoperative serum sodium, potassium, calcium, magnesium, urea, creatinine, blood sugar, hemoglobin, and hematocrit values are detected to be abnormal.

30 patients who were eligible for the study were given detailed information about the study and an informed consent form was signed. Forms detailing the patients' demographic characteristics and pre-operative measurements were completed.

Randomization:

Patients included in the study were divided into 2 groups using a random number table. In Group I (n = 15) Levobupivacaine and in Group II (n = 15) Bupivacaine was performed (Figure 1).




Figure 1: Flow chart of the study

Interventions:

Before surgery: Patients were taken to the block room 30 minutes before the procedure and IV infusion of 7mL/kg 0.9% NaCl was started. Both groups were monitored as standard. These were noninvasive blood pressure [systolic arterial pressure (SAP), diastolic arterial pressure (DAP), mean arterial pressure (MAP)] and heart rate (HR).

Surgery Period: After the preoperative follow-up values of the patients were taken, they were sedated with IV Dormicum (loading dose: 0.015 mg / kg and id: 0.06 mg / kg / hr) in a separate vein route. Later, the patient was placed in a side-lying position and through the range L₃₋₄ or L₄₋₅ the epidural range was reached with 18 G Tuohy

epidural needle by using the resistance loss method with saline, with openness towards cephal. The subarachnoid space was entered with a 27G spinal needle sent through the epidural needle. After the flow of cerebrospinal fluid (CSF) was observed, spinal anesthesia was completed by administering 15 mg (3 cc) isobaric levobupivacaine in Group I and 15 mgr (3 cc) isobaric bupivacaine in Group II. The spinal needle was retracted, the 20 G epidural catheter was advanced through the epidural needle for 3 cm, and the patient was brought to the supine position after being properly fixed. After appropriate site cleaning from the patients venous blood was collected 5 minutes after the spinal anesthesia procedure to determine the level BNP protein through the antecubital vein. The sensory

block level was checked with a pinprick test every 5 minutes. When the sensory block reached T₁₀, venous blood was collected from antecubital vein to measure again the level of BNP after appropriate field cleanup, and surgical procedure was started. During the operation, the patient was treated with a mask of 3 lt / min O₂ mask.

The first follow-up was accepted as 0. minute immediately after the combined spinal epidural. SAP, DAP, and HR values were recorded and mean values were calculated from the 0 moment to the end of the surgery at the 5th, 10th, 15th, 20th, 25th, 30th, 45th, 60th, 90th, 120th minutes. During the surgery when HR was lowered to below 50 / min. , atropine 0.5 mg (IV) was applied and when OAP control value was lowered to below 20% ephedrine 10 mg (IV) was applied.

Post Surgery Period: Patient was informed about patient-controlled analgesia (PCA) and the use of PCA device during the preoperative visit. With the termination of the surgery, the PCA device was connected to the epidural catheter and local anesthetic infusion was performed with PCA. The loading dose was not applied in PCA. The basal infusion rate was set at 4 mL / h, the bolus dose was 2 mL, and the locking time was set to 30 minutes in PCA device. Concentrations in groups were: Group I: 1.25 mg / ml levobupivacaine, Group II: 1.25 mg / ml bupivacaine. SAP, DAP, HR, visual analog scale (VAS) values were observed at postoperative follow-up time of 0. min and at 1, 6, 12, 24 hours. In addition, diclofenac 75 mg (IM) was administered at times of VAS > 4 and the data were recorded.

In addition, during the operation and post-operative period side effects occurred in the patients were followed and necessary treatments were performed. Nausea-vomiting, bradycardia, and hypotension were followed and recorded if observed. When these side effects were observed, metoclopramide was treated with 10 mg (IV), atropine 0.5 mg (IV), ephedrine 10 mg (IV), respectively.

Venous blood samples were taken from antecubital vein at 24th postoperative hour for the measurement of BNP protein level after appropriate site cleanup.

Evaluation Parameters:

Blood samples were taken in a red capped dry biochemical tube and delivered to the biochemistry laboratory within 15 minutes after being taken. Serum BNP measurements were performed in our hospital's biochemistry laboratory. After centrifugation for 10 min at 5000 rpm, it was worked on Axsym device using the Abbott Axsym System BNP kit with the MEIA (microparticle enzyme immunoassay). Before testing, samples were brought to room temperature to ensure homogeneity. The results were given in pg / ml. Patients were assessed for BNP levels below or above 100 pg / mL.

Statistical Analysis

SPSS 22.0 statistical package program was used to analyze the data. When the data were evaluated, frequency distributions, averages, standard deviations, percent values and cross tables were used. Categorical comparisons were made using Chi-Square or Fisher's exact test. In the study, Student's t-Test was used to compare the difference between the groups. The probability (P) values $\alpha = 0.05$ are considered to be significant and there is a difference between the groups, the larger values are considered to be insignificant and there is no difference between the groups.

RESULTS

The current study was completed with a total of 30 patients (Group I n = 15, Group II n = 15) (Figure 1). Distribution of age, gender, body mass index (BMI) of the patients are presented in Table 1. There was no statistically significant difference between the two groups for demographic characteristics ($p > 0.05$).

Table 1: Comparison of the demographic characteristics of the patients (Mean \pm SD)

	Group I (n=15)	Group II (n=15)	P
Age (Year)	62.67 \pm 4.66	61.47 \pm 6.26	0.845
Gender (M/F)	1/14	1/14	N/A
BMI (kg/m ²)	30.42 \pm 3.44	29.95 \pm 3.31	0.705
Duration of Surgery (min)	86 \pm 21.5	90 \pm 18	0.711

M: Male, F: Female, BMI: Body mass index

There was no statistically significant difference in systolic arterial pressures ($p > 0.05$) between the groups at all measurement times except for postoperative 1st hour. But there was a statistically significant difference ($p < 0.05$) in

the bupivacaine group at postoperative 1st hour (Table 2). Diastolic arterial pressures were not statistically different between groups at all measurement times ($p > 0.05$) (Table 2).

Table 2: Comparison of the SAP and DAP values between the groups

SAP	Group I (n=15)	Group II (n=15)	p
preoperative	161.33 \pm 26.07	148.07 \pm 19.76	0.127
mean pressure during operation	131.96 \pm 20.46	124.22 \pm 17.97	0.281
postoperative	131.67 \pm 22.07	121.80 \pm 12.19	0.141
postoperative 1 st hour	130.53 \pm 12.44	120.67 \pm 10.63	0.027
postoperative 6 th hour	126.67 \pm 13.10	124.40 \pm 11.58	0.620
postoperative 12 th hour	127.93 \pm 9.84	124.07 \pm 8.84	0.267
postoperative 24 th hour	126.00 \pm 14.24	118.80 \pm 8.51	0.104
DAP			
preoperative	87.87 \pm 16.35	84.67 \pm 11.65	0.542
mean pressure during operation	72.08 \pm 11.45	71.10 \pm 11.17	0.815
postoperative	73.67 \pm 12.16	67.67 \pm 7.83	0.119
postoperative 1 st hour	71.80 \pm 12.53	69.60 \pm 5.42	0.538
postoperative 6 th hour	72.27 \pm 10.07	74.40 \pm 6.62	0.499
postoperative 12 th hour	72.80 \pm 11.68	72.53 \pm 8.90	0.944
postoperative 24 th hour	74.40 \pm 8.55	69.15 \pm 6.62	0.085

SAP: systolic arterial pressure, DAP: diastolic arterial pressure

Comparison of mean arterial pressures between groups; There was a statistically significant difference ($p < 0.05$) at the end of the operation, postoperative 1st hour and postoperative 24th hour, in the bupivacaine group (Table 3). Comparison of heart rate between groups; There

was no statistically significant difference between the groups at all measurement times except 24 hours postoperatively ($p > 0.05$). There was a statistically significant difference in the levobupivacaine group at postoperative 24th hour ($p < 0.05$) (Table 3).

Table 3: Comparison of the MAP and heart rate values between the groups

MAP	Group I (n=15)	Group II (n=15)	p
preoperative	111.40±26.11	104.60±11.93	0.367
mean pressure during operation	93.37±15.52	88.31±13.93	0.355
postoperative	100.27±14.04	88.67±11.02	0.018
postoperative 1 st hour	101.20±11.45	90.27±7.87	0.005
postoperative 6 th hour	95.33±12.87	92.87±10.03	0.563
postoperative 12 th hour	94.13±12.74	95.60±8.92	0.718
postoperative 24 th hour	97.87±10.87	90.33±8.72	0.045
HEART RATE			
preoperative	89.93±19.07	93.53±12.11	0.542
mean pressure during operation	77.21±14.28	79.50±8.60	0.599
postoperative	80.93±12.78	78.00±11.38	0.512
postoperative 1 st hour	81.67±15.97	78.40±11.41	0.524
postoperative 6 th hour	77.27±11.34	77.33±9.21	0.986
postoperative 12 th hour	76.80±12.73	76.93±8.08	0.973
postoperative 24 th hour	78.93±6.68	81.20±6.46	0.512

MAP: mean arterial pressure

Comparison of VAS values between groups; There was no statistically significant difference at all measurement times except postoperative 12th and 24th hours ($p > 0.05$). A statistically

significant difference was found in the VAS values measured at postoperative 12th hour and 24th hour in favor of levobupivacaine group ($p < 0.05$) (Table 4).

Table 4: Comparison of the VAS values between the groups

VAS	Group I (n=15)	Group II (n=15)	p
postoperative	2.47±1.46	2.00±1.51	0.397
postoperative 15 th minute	3.00±1.89	2.53±1.85	0.500
postoperative 30 th minute	3.07±1.49	3.20±1.57	0.813
postoperative 1 st hour	3.53±1.19	4.00±1.56	0.364
postoperative 6 th hour	3.60±1.24	4.13±0.99	0.204
postoperative 12 th hour	3.47±1.06	4.93±0.96	<0.001
postoperative 24 th hour	4.00±0.93	4.93±1.10	0.018

VAS: Visual analog scale

In comparison between the BNP levels between the groups; no statistically significant difference was

found between the two groups at all measurement times ($p > 0.05$) (Table 5).

Table 5: Comparison of the BNP values between the groups.

BNP	Group 1 (n=15)	Group 2 (n=15)	p
after injection 15 th minute			
BNP<100	12 (%80)	14 (%93.3)	0.299
BNP>100	3 (%20)	1 (%6.7)	
when the sensory block reaches T10 level			
BNP<100	13 (%86.7)	15 (%100)	0.153
BNP>100	2 (%13.3)	-	
postoperative 24 th hour			
BNP<100	11 (%73.3)	13 (% 86.7)	0.379
BNP>100	4 (%26.7)	2 (%13.3)	

BNP: Brain Natriuretic Peptide

DISCUSSION

In our study in which combined spinal epidural anesthesia (CSEA) was used for total knee arthroplasty and for postoperative analgesia, we used bupivacaine and levobupivacaine in equal doses. As a result of our study, there was no statistically significant difference between preoperative, postoperative and postoperative 24th hour values in the BNP levels used to determine the cardiotoxic effects of the drugs given.

It is indicated that the cardiovascular toxicity potentials of local anesthetic drugs are due not only to the nerve cell membranes but also to the ion channels in excitable tissues such as the heart⁹. The primary mechanism of bupivacaine-induced cardiotoxicity has been reported as cardiac sodium channels and voltage-dependent potassium channels being blocked with bupivacaine and the prolongation of the duration of action of bupivacaine's cardiac action potential¹⁰. The enantiomers of bupivacaine have pharmacologically different properties and have been developed to reduce the risk of fatal arrhythmias that can occur with bupivacaine. Levobupivacaine is the (-) enantiomer of bupivacaine. Levobupivacaine shows similar pharmacokinetic properties to racemic bupivacaine, and studies have shown that the duration of effect onset and duration of effect and

hemodynamic changes after spinal anesthesia of levobupivacaine is the same as that of bupivacaine^{7,11}. It has been reported that the inhibitory effect of bupivacaine on sodium and potassium channels is more potent than levobupivacaine. Levobupivacaine has therefore been reported to be a new alternative in patients with cardiovascular disease. However, it is stated that studies with Levobupivacaine are not enough and more studies should be done^{12,13}.

In the literature on cardiotoxicity of local anesthetics, animal studies and limited number of human studies have been tried to be shown¹³⁻¹⁹. In the first of these studies, Groban et al. injected high doses of bupivacaine, levobupivacaine, ropivacaine and lidocaine intravenously into the dogs and investigated their cardiotoxic effects. Lidocaine intoxication resulted in myocardial depression responding to resuscitation, whereas bupivacaine, levobupivacaine and ropivacaine did not always respond to resuscitation successfully. Mortality rates were 50% in bupivacaine, 30% in levobupivacaine, 10% in ropivacaine and 0% in lidocaine¹³. Other studies have reported that plasma concentrations of bupivacaine, levobupivacaine, and ropivacaine are similar when cardiovascular collapse occurs¹⁴. Ohmura et al. reported that there was no difference in plasma concentrations of bupivacaine, levobupivacaine, and ropivacaine when asystole occurred in anesthetized rats¹⁵. The

ratio of bupivacaine, levobupivacaine and ropivacaine, which prolong the QRS period in isolated rabbit hearts, was found to be 1: 0.4: 0.3 in another study ¹⁶.

In studies where people were used, local anesthetics were administered intravenously in small doses to volunteers and the toxicity of the local anesthetics on the cardiovascular system was investigated. As a result of the study, we found that ropivacaine and levobupivacaine are at the same level of toxicity but bupivacaine is more toxic than these ¹⁷. In another volunteer study, there was a statistically significant difference only in the change in bupivacaine group despite the increase in PR interval and corrected QT (QTc) intervals in ECG of levobupivacaine and bupivacaine ¹⁸. Salomaki et al. reported that levobupivacaine is a potent drug and that serious precautions should be taken to prevent intravenous administration in case reports in which they reported that they had observed cardiovascular collapse after unintentional intravenous infusion of levobupivacaine under general anesthesia and they treated without sequel ¹⁹. In another study, epidural bupivacaine and levobupivacaine in cesarean section did not differentiate in QT interval measurements of ECG ⁶.

Cardiovascular effects of local anesthetics can be observed with ECG findings but also biochemical markers can be used to detect cardiac dysfunction. In function disorders, many natriuretic peptides are released from the heart, and one of the most sensitive and up-to-date of these released peptides is the brain natriuretic peptide (BNP) ⁸. It is stated in the literature that BNP, apart from cardiac diseases, can also be used for cardiotoxicity, cardiac and noncardiac post-surgery situation, and cardiac status ^{21,22,23}.

For this purpose, NT-ProBNP levels before and after surgery were investigated in patients who underwent vascular surgery. They have reported that simple postoperative NT-ProBNP levels may lead to detecting structural myocardial injury ²¹. In their studies Terasako et al. have suggested that elevated ANP and BNP levels in patients with hip arthroplasty may be indicative of insufficient myocardial reserves associated with hypotension and may allow detection of patients at risk for complications ²². They also reported that, in a prospective cohort study of BNP levels to determine the risk of complications and increased mortality following major emergency non-cardiac surgery, BNP measurement is important for differentiating the patients with increased risk of preoperative cardiac events ²⁴. In their study

Vetrugno et al. have shown that BNP before and after surgery is predictive of significant cardiac side effects ²⁵.

Many of the studies in the literature on cardiotoxicity have been based on the effects of bupivacaine and levobupivacaine on cardiac message ^{6,18}. Although studies report that bupivacaine is more cardiotoxic, there are studies that have found cardiotoxic effects similar to levobupivacaine ^{14,15}. When the studies are examined, there is no other study evaluating the cardiotoxic effects of different types of local anesthetic drugs with BNP.

The cardiotoxic effects of levobupivacaine and bupivacaine, which we determined as the aim of our study, were not different when evaluated with BNP. Unlike the literature, in this study the BNP pathologic limit value was determined and values over this limit value were accepted as significant or meaningful. In this study where 100 pg / mL was accepted as pathologic value, we think it is more important that there should be no difference between measurement times between the two groups. On the other hand, the veins in the non-valvular structure on the epidural side are directly connected to the pelvic veins (lower), and intracranial veins (above), and to the thoracic and abdominal veins via intervertebral foramens. With this epidural injection, the local anesthetic delivered can reach these veins and from there to the heart or brain ^{1,6}. 24th hour BNP values were no different either between groups in order to detect cardiac effects of bupivacaine and levobupivacaine in infusion doses for this purpose. In hemodynamic parameters determined in other results of the study, differences in some measurement times do not seem meaningful as they are independent of BNP protein measurement times and is small in number.

Limitation: The lack of a placebo intervention group and the small number of patients are the obvious limitations of this study.

CONCLUSION

In these study results, similar results were obtained in intraoperative and postoperative BNP levels when using levobupivacaine and bupivacaine in equal doses for both spinal anesthesia and epidural analgesia.

REFERENCES

1. Erdine S, Özyalçın SN, Raj PP, et al. Rejyonel Anestezi. İstanbul: Nobel Tıp Kitabevleri;2005; p.185-91.
2. Rawal N, Holmstrom B, Crowhurst JA, Van Zundert A. The combined spinal- epidural

- technique anesthesiology. *Anesthesiol Clin North America*. 2000; 18: 267-95.
3. Collins JV. *Principles of Anaesthesiology*. Third Edition. Philadelphia Lea and Febiger; 1993; p.1445-97.
 4. Chester C, Bleckner LL. Anaesthetic agents for advanced regional anaesthesia. *Drug*. 2005; 65: 745-59.
 5. Kayhan Z. *Klinik Anestezi*. 2. Baskı. İstanbul Logos Yayıncılık; 2004; p. 503-23.
 6. Bader AM, Tsen LC, Camann WR, Nephew E, Datta S. Clinical effects and maternal and fetal plasma concentrations of %0,5 epidural levobupivacaine versus bupivacaine for cesarean delivery. *Anesthesiology*. 1999; 90: 1596-601.
 7. Casati A, Moizo E, Marchetti C, Vinciguerra F. A prospective, randomized, double-blind comparison of unilateral spinal anesthesia with hyperbaric bupivacaine, ropivacaine, or levobupivacaine for inguinal herniorrhaphy. *Anesth Analg*. 2004; 99:1387-92.
 8. Suttner SW, Boldt J. Natriuretic peptide system: physiology and clinical utility. *Curr Opin Crit Care*. 2004;10: 336-41.
 9. Valenzuela C, Snyders DJ, Bennett PB, Tamargo J, Hondeghem LM. Stereoselective block of cardiac sodium channels by bupivacaine in guinea pig ventricular myocytes. *Circulation*.1995; 92: 3014-24.
 10. Kawano T, Oshita S, Takahashi A, et al. Molecular mechanisms of the inhibitory effects of bupivacaine, levobupivacaine, and ropivacaine on sarcolemmal adenosine triphosphate-sensitive potassium channels in the cardiovascular system. *Anesthesiology*. 2004; 101: 390-8.
 11. Cuvas O, Er AE, Ongen E, Basar H. Spinal anesthesia for transurethral resection operations: bupivacaine versus levobupivacaine. *Minerva Anesthesiol*. 2008;74:697-701.
 12. Fatorini F, Ricci Z, Rocco A, et al. Levobupivacaine versus racemic bupivacaine for spinal anaesthesia in orthopaedic major surgery. *Minerva Anesttesiol*. 2006; 72: 637-44.
 13. Groban L, Deal DD, Vernon JC, James R L, Butterworth J. Cardiac resuscitation after incremental overdosage with lidocaine, bupivacaine, levobupivacaine, and ropivacaine in anesthetized dogs. *Anesth Analg*. 2001; 92: 37-43.
 14. Groban L, Deal DD, Vernon JC, James RL, Butterworth J. Ventricular arrhythmias with or without programmed electrical stimulation after incremental overdosage with lidocaine, bupivacaine, levobupivacaine, and ropivacaine. *Anesth Analg*. 2000; 91: 1103-11.
 15. Ohmura S, Kawada M, Ohta T, Kobayashi T. Systemic toxicity and resuscitation in bupivacaine, levobupivacaine or ropivacaine infused rats. *Anesth Analg* 2001; 93: 743-8.
 16. Mazoit JX, Decaux A, Bouaziz H, Eduard A. Comparative ventricular electrophysiologic effect of rasemic bupivacaine, levobupivacaine and ropivacaine on the isolated rabbit heart. *Anesthesiology* 2000; 93: 784-92.
 17. Stewart J, Kellett N, Castro D. The central nervous system and cardiovascular effects of levobupivacaine and ropivacaine in healthy volunteers. *Anesth Analg*. 2003;97: 4126.
 18. Bardsley H, Griswood R, Baker H, Nimmo W. A comparison of the cardiovascular effects of levobupivacaine and rac-bupivacaine following intravenous administration to healthy volunteers. *Br J Clin Pharmacol* 1998; 46: 245-9.
 19. Salomaki TE, Laurilla PA, Ville J. Successful resuscitation after cardiovascular collapse following accidental intravenous infusion of levobupivacaine during general anesthesia. *Anesthesiology* 2005; 103: 1095-6.
 20. Karakılıç E, M Ali Karaca, Bozkurt Ş, Coşkun F, Sivri B. BNP Nedir? Acil Serviste Beyin Natriüretik Faktör (BNP) Kullanımı. *Akademik Acil Tıp dergisi*. 2005; 3: 7-10.
 21. Mahla E, Baumann A, Rehak P, et al. N-terminal pro-brain natriuretic peptide identifies patients at high risk for adverse cardiac outcome after vascular surgery. *Anesthesiology*. 2007; 106:1088-95.
 22. Terasako K. Perioperative plasma concentrations of atrial and brain natriuretic peptides in patients undergoing hip arthroplasty. *Anaesth Intensive Care*. 2002; 30: 588-90.
 23. Pongprot Y, Sittiwangkul R, Charoenkwan P, Silvilairat S. Use of Cardiac Markers for Monitoring of Doxorubicin-induced Cardiotoxicity in Children With Cancer. *Journal of Pediatric Hematology/Oncology*. 2012; 34: 589-95.
 24. Cuthbertson BH, Card G, Croal BL, McNeilly J, Hillis GS. The utility of B-type natriuretic peptide in predicting postoperative cardiac events and mortality in patients undergoing major emergency non-cardiac surgery. *Anaesthesia*. 2007; 62: 875-81.

25. Vetrugno L, Langian N, Gisonni R, et al. Prediction of early postoperative major cardiac events after elective orthopedic surgery: the role of B-type natriuretic peptide, the revised cardiac risk index, and ASA class. *BMC Anesthesiology*. 2014; 14: 20.